Results 91 to 100 of about 64,427 (282)

Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies

MedComm, Volume 6, Issue 3, March 2025.
The figure highlights the interplay of genetic and epigenetic mechanisms in pulmonary hypertension (PH) and their implications for therapeutic strategies. The genetic mechanism section features key genes implicated in PH pathogenesis. The epigenetic mechanism encompasses DNA methylation, RNA methylation, noncoding RNAs (miRNA, lncRNA), and histone ...
Joseph Adu‐Amankwaah, Qiang You, Xiaoer Liu, Jiayi Jiang, Dongqi Yang, Kuntao Liu, Jinxiang Yuan, Yanfang Wang, Qinghua Hu, Rubin Tan   +9 more
wiley   +1 more source

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

Molecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu, Chuting Li, Rui Su, Zhao Yin, Guiping Huang, Juhua Yang, Zhendong Li, Keda Zhang, Jia Fei   +8 more
doaj  

Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma [PDF]

, 2011
Imatinib mesylate (IM) is a compound that inhibits both BCR-ABL tyrosine kinase and c-kit receptors. Tyrosine kinases are important in cellular signaling and mediate major cellular processes such as proliferation, differentiation, apoptosis, attachment ...
Abourbih, Daniel, Antecka, Emilia, Belfort Neto, Rubens, Burnier Júnior, Miguel Nascente, Castiglione, Enzo, Di Cesare, Sebastian, Fernandes, Bruno F., Isenberg, Jordan, Maloney, Shawn, Martins, Claudia   +9 more
core   +2 more sources

Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy

eJHaem, Volume 6, Issue 1, February 2025.
Abstract Introduction Benralizumab is an interleukin 5‐receptor‐blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase‐II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase‐III trial.
Yvonne Veltman, Anna M. Aalbers, Maud A. W. Hermans, Pim G. N. J. Mutsaers   +3 more
wiley   +1 more source

Treatment of a feline cutaneous mast cell tumour using imatinib mesylate as a neoadjuvant tyrosine kinase inhibitor therapeutic agent

Veterinární Medicína, 2020
A two-year-old spayed female American shorthair cat presented with a rough, circular, exophytic mass on the genital area. The clinical findings and histopathological examination revealed that the mass contained neoplastic mast cells and, thus, was ...
Joonyoung Kim, Ha-Jung Kim
doaj   +1 more source

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [PDF]

, 2004
Imatinib mesylate (STI571), a potent tyrosine kinase inhibitor, is successfully used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. However, the intended chronic oral administration of imatinib may
Boersma, A.W.M. (Anton), Brok, M. (Mariël), Burger, H. (Herman), Nooter, K. (Kees), Stoter, G. (Gerrit), Tol, H. van, Wiemer, E.A.C. (Erik)   +6 more
core   +1 more source

Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Advanced Science, Volume 12, Issue 4, January 27, 2025.
Tumors develop resistance to therapeutic agents, unfortunately, efforts to overcome resistance have achieved limited success. m6A RNA modification dysregulation is an emerging mechanism for cancer therapy resistance. This review comprehensively discusses recent studies regarding the contributions of m6A modification and its regulators to cancer therapy
Mohammad Burhan Uddin, Zhishan Wang, Chengfeng Yang   +2 more
wiley   +1 more source

A retrospective observational study of patients with melanoma prescribed combined BRAF and MEK inhibitors in a real‐world treatment setting in Japan

Malignancy Spectrum, Volume 1, Issue 4, Page 312-322, December 2024.
Melanoma patients initiating treatements with dabrafenib + trametinib (Dab + Tram, n = 74; 67 non‐adjuvant and seven adjuvant) or encorafenib + binimetinib (Enco + Bini, n = 16) were identified in the Japanese MDV database. Median treatment duration was 11.8 months with Dab + Tram and 8.1 months with Enco + Bini.
Kenjiro Namikawa, Kok Yew Ngew, Zuzanna Lukowicz, Ryosuke Kano   +3 more
wiley   +1 more source

Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia

Eurasian Journal of Medicine, 2011
Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak, Harika Celebi, Aynur Albayrak, Esra Saribacak Can, Vedat Aslan, Birgul Onec, Ipek Coban   +6 more
doaj  

18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report

Case Reports in Oncological Medicine, 2011
Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
Kazunori Otsuka, Masahiro Takahashi, Hiroshi Nanjo, Hideaki Miyazawa, Masatake Iida, Yuki Abe, Mario Jin, Hirohide Onishi, Manabu Hashimoto, Yuzo Yamamoto, Hiroyuki Shibata   +10 more
doaj   +1 more source